These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11093361)

  • 21. Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
    Baxter AD; Bhogal R; Bird J; Keily JF; Manallack DT; Montana JG; Owen DA; Pitt WR; Watson RJ; Wills RE
    Bioorg Med Chem Lett; 2001 Jun; 11(11):1465-8. PubMed ID: 11378378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer.
    Tierney GM; Griffin NR; Stuart RC; Kasem H; Lynch KP; Lury JT; Brown PD; Millar AW; Steele RJ; Parsons SL
    Eur J Cancer; 1999 Apr; 35(4):563-8. PubMed ID: 10492628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug.
    Failes TW; Cullinane C; Diakos CI; Yamamoto N; Lyons JG; Hambley TW
    Chemistry; 2007; 13(10):2974-82. PubMed ID: 17171733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.
    Nemunaitis J; Poole C; Primrose J; Rosemurgy A; Malfetano J; Brown P; Berrington A; Cornish A; Lynch K; Rasmussen H; Kerr D; Cox D; Millar A
    Clin Cancer Res; 1998 May; 4(5):1101-9. PubMed ID: 9607566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The matrix metalloproteinase inhibitor marimastat inhibits seizures in a model of kainic acid-induced status epilepticus.
    Pijet B; Konopka A; Rejmak E; Stefaniuk M; Khomiak D; Bulska E; Pikul S; Kaczmarek L
    Sci Rep; 2020 Dec; 10(1):21314. PubMed ID: 33277582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts.
    Skipper JB; McNally LR; Rosenthal EL; Wang W; Buchsbaum DJ
    ORL J Otorhinolaryngol Relat Spec; 2009; 71(1):1-5. PubMed ID: 18931526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastric cancer. Treatment of advanced disease and new drugs.
    Caponigro F; Facchini G; Nasti G; Iaffaioli RV
    Front Biosci; 2005 Sep; 10():3122-6. PubMed ID: 15970566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma.
    Gabelloni P; Da Pozzo E; Bendinelli S; Costa B; Nuti E; Casalini F; Orlandini E; Da Settimo F; Rossello A; Martini C
    Neuroscience; 2010 Jun; 168(2):514-22. PubMed ID: 20382206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer.
    Jones L; Ghaneh P; Humphreys M; Neoptolemos JP
    Ann N Y Acad Sci; 1999 Jun; 880():288-307. PubMed ID: 10415874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196.
    Zucker S; Wang M; Sparano JA; Gradishar WJ; Ingle JN; Davidson NE;
    Clin Breast Cancer; 2006 Feb; 6(6):525-9. PubMed ID: 16595036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The matrix metalloproteinase inhibitor marimastat promotes neural progenitor cell differentiation into neurons by gelatinase-independent TIMP-2-dependent mechanisms.
    Sinno M; Biagioni S; Ajmone-Cat MA; Pafumi I; Caramanica P; Medda V; Tonti G; Minghetti L; Mannello F; Cacci E
    Stem Cells Dev; 2013 Feb; 22(3):345-58. PubMed ID: 23098139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
    Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Marimastat. BB 2516, TA 2516.
    Drugs R D; 1999 Feb; 1(2):146-9. PubMed ID: 10566011
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of marimastat on serum tumour markers in patients with colorectal cancer.
    North H; King J; Morris DL
    Int J Surg Investig; 2000; 2(3):213-7. PubMed ID: 12678521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
    Rosenbaum E; Zahurak M; Sinibaldi V; Carducci MA; Pili R; Laufer M; DeWeese TL; Eisenberger MA
    Clin Cancer Res; 2005 Jun; 11(12):4437-43. PubMed ID: 15958628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease.
    Treharne GD; Boyle JR; Goodall S; Loftus IM; Bell PR; Thompson MM
    Br J Surg; 1999 Aug; 86(8):1053-8. PubMed ID: 10460642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical potential of matrix metalloprotease inhibitors in cancer therapy.
    Heath EI; Grochow LB
    Drugs; 2000 May; 59(5):1043-55. PubMed ID: 10852638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease.
    Sykes AP; Bhogal R; Brampton C; Chander C; Whelan C; Parsons ME; Bird J
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1535-42. PubMed ID: 10571613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional biomarkers of musculoskeletal syndrome (MSS) for early in vivo screening of selective MMP-13 inhibitors.
    Mazurek SG; Li J; Nabozny GH; Reinhart GA; Muthukumarana AC; Harrison PC; Fryer RM
    J Pharmacol Toxicol Methods; 2011; 64(1):89-96. PubMed ID: 21376127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.